Glixis Therapeutics spun out of UC technology in 2012 and was co-founded by UC professor of neurology Michael Demetriou MD PhD, University of Toronto research chair and professor James Dennis PhD and Ani Oganesyan PhD and CEO. Under the guidance of world-renowned leaders, Glixis Therapeutics is developing a first-of-its-kind compound for progressive Multiple Sclerosis for which no FDA-approved treatment currently exists. Glixis Therapeutics combines a leading candidate drug for progressive MS with a development pipeline including a proprietary diagnostic technology as well as proprietary genetic testing technology for progressive MS. This integrated approach supports significant changes to the current therapeutic landscape for MS and the potential for personalized medicine.
At Glixis Therapeutics, our purpose is to fundamentally revolutionize the potential therapies of autoimmune disease by treating the underlying pathophysiology. Current therapies often broadly and non-specifically suppress the immune system, a questionable therapeutic strategy given our increasing understanding of the pathogenic mechanisms promoting disease. We are dedicated to bringing significant life-altering medical treatments to market and improving patient lives.
At Glixis Therapeutics, we are developing new and improved drugs, diagnostic technology, and genetic testing to provide an integrated and personalized approach to medical care. Our focus is on the greatest unmet needs and we strive to deliver innovative healthcare for a better tomorrow.
Michael Demetriou, M.D. Ph.D.
Neurology and Microbiology & Molecular Genetics
Dr. Demetriou is a practicing Neurologist at UC Irvine Health and is a Professor in Departments of Neurology and Microbiology & Molecular Genetics at UC Irvine. His research is focused on the pathophysiology and treatment of Multiple Sclerosis. He holds many positions related to field of medical practice and scientific research. He is the director of the Multiple Sclerosis Program at UC Irvine, the director of the National Multiple Sclerosis Society Designated Comprehensive Care Clinic at UC Irvine, and the associate director of the Multiple Sclerosis Research Center at UC Irvine. He is also Co-founder of Glixis Therapeutics, LLC.
James W. Dennis, Ph.D.
Professor in the Department of Molecular Genetics and Microbiology
Dr. Dennis is a Professor in the Department of Molecular Genetics and Microbiology at the University of Toronto, Ontario, a senior research investigator at the Samuel Lunenfeld Research Institute at Mount Sinai Hospital in Toronto, Ontario, and a Fellow of the Royal Society of Canada. His research is focused on the pathophysiology and treatment of Multiple Sclerosis. He is also Chair of Business Advisory Board and Co-founder of Glixis Therapeutics, LLC.
Ani Oganesyan, Ph.D.
Chief Scientific Officer
Dr. Oganesyan is Chief Scientific Officer of Glixis Therapeutics. She completed her PhD and post-doctoral training at the University of California, Irvine, which included a National Institutes of Health (NIH) National Research Service Award (F32 Fellowship Award). Her research was focused on the pathophysiology and treatment of Multiple Sclerosis. She is also a Co-founder of Glixis Therapeutics, LLC.